

Reference: FOI.ICB-2223/100

Subject: Continuous Glucose Monitoring and Hybrid Closed Loop Commissioning Policies

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
<p>1. a) Is there currently a commissioning policy at Bristol, North Somerset and South Gloucestershire ICB for Continuous Glucose Monitoring (CGM) for people with a diagnosis of type 1 diabetes (Adults & Pediatrics); and b) could a copy of the commissioning policy be shared?</p> <p>If yes to 1a), has the CGM policy been updated to reflect the recommendations from the updated NICE Diabetes Guidelines (NG 17, NG18 & NG28) published in March 2022?</p> <p>If no to 1a), when is the CGM policy for both adults and pediatrics expected to be in place?</p>	<p>a) We do not hold a commissioning policy at Bristol, North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB) for Continuous Glucose Monitoring (CGM) for people with a diagnosis of type 1 diabetes (Adults & Paediatrics). We have a 'Clinical Pathway for the use of diabetes technologies in all patients with Type 1 Diabetes'.</p> <p>b) The pathway can be accessed through the BNSSG Formulary website on Remedy at: https://remedy.bnssgccq.nhs.uk/formulary-adult/local-guidelines/6-endocrine-system-guidelines/</p> <p>The pathway and CGM policy have been updated to reflect the recommendations from the updated NICE Diabetes Guidelines NG17 and NG18 that were published in March 2022.</p> <p>We are working as a system on the implementation of NG28 for Type 2 diabetes and expect this to be agreed in early in the New Year 2023.</p>

<p>2. Has Bristol, North Somerset and South Gloucestershire ICB agreed on any plans to commission hybrid closed loop technology (HCL) insulin pumps in the 2023-24 NHS financial year? Could these plans be disclosed?</p>	<p>There is provision of CGM plus insulin pump therapy within the 'Clinical Pathway for the use of diabetes technologies in all patients with Type 1 Diabetes' in specific circumstances.</p> <p>When the NICE TA in development for hybrid closed loop systems is published, we will review our pathway in line with any NICE recommendations.</p>
<p>3. How many individuals have HCL pump funding support across your Bristol, North Somerset and South Gloucestershire ICB?</p>	<p>This information is not held by BNSSG ICB. Please contact the provider Trusts;</p> <p>North Bristol NHS Trust (NBT) – https://www.nbt.nhs.uk/about-us/information-governance/freedom-of-information/request-information</p> <p>University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) – https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests</p>
<p>4. Has Bristol, North Somerset and South Gloucestershire ICB held any meeting(s) to discuss financial planning in the context of commissioning hybrid closed loop technology (HCL) for 2023-34 NHS financial year? And could any meetings minutes relevant to this question be disclosed?</p>	<p>No meetings have been held.</p>

The information provided in this response is accurate as of 24 November 2022 and has been approved for release by Rosi Shepherd, Chief Nurse for NHS Bristol, North Somerset and South Gloucestershire ICB.